Keywords: پروتوزومب; Pertuzumab; CHO-K1 cells; Gene optimization; Signal peptide; Transient transfection;
مقالات ISI پروتوزومب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پروتوزومب; Esophagogastric cancer; HER2; Targeted therapy; Trastuzumab; Pertuzumab; TDM-1; Lapatinib;
Keywords: پروتوزومب; PT, phyllodes tumor; BC, breast cancer; FA, fibroadenomaBreast cancer; Phyllodes tumor; Docetaxel; Trastuzumab; Pertuzumab
Keywords: پروتوزومب; Cardiomyopathy; Trastuzumab; Lapatinib; Pertuzumab; Breast cancer
Keywords: پروتوزومب; Metastatic breast cancer; HER2; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Resistance; Management; Novel therapy;
Keywords: پروتوزومب; Breast cancer; Adverse events; Trastuzumab; Pertuzumab; Lapatinib; Bevacizumab; Trastuzumab-emtansine; Everolimus; ABC; advanced breast cancer; QoL; quality of life; AE; adverse event; HER2; human epidermal growth factor receptor type 2; LVEF; left ventri
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results
Keywords: پروتوزومب; Observational study; Real life; Pertuzumab; Breast cancer; Trastuzumab; Clinical practice; HER2; Docetaxel; Paclitaxel;
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive ea
Keywords: پروتوزومب; Neoadjuvant therapy; Pertuzumab; Trastuzumab; Breast cancer; Safety; Cardiotoxicity; Clinical efficacy; Disease-free survival;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
Keywords: پروتوزومب; Aflibercept; Bevacizumab; Cetuximab; Infection; Pertuzumab; Small-molecule inhibitors; Trastuzumab; Tyrosine kinase inhibitors; VEGF-targeted agents;
First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
Keywords: پروتوزومب; Eribulin; HER2-positive advanced breast cancer; Non-taxane microtubule dynamic inhibitor; Pertuzumab; Trastuzumab;
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Keywords: پروتوزومب; Trastuzumab; Pertuzumab; T-DM1; HER2/neu; Epithelial ovarian carcinoma;
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study
Keywords: پروتوزومب; Breast neoplasms; Cohort studies; Palliative care; Outpatients; Real-world data; Registries; ABC; advanced breast cancer; AGO; Arbeitsgemeinschaft Gynäkologische Onkologie; Bev; bevacizumab; C; cyclophosphamid; Cap; capecitabine; Car; carboplatin; CCI; C
Systematic reviewConcurrent administration of anti-HER2 therapy and radiotherapy: Systematic review
Keywords: پروتوزومب; Irradiation; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Concomitant;
Advances in the management of HER2-positive early breast cancer
Keywords: پروتوزومب; Breast cancer; HER2; Trastuzumab; T-DM1; Neratinib; Pertuzumab; Lapatinib;
A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer
Keywords: پروتوزومب; Immunohistochemistry; Neratinib; Personalized medicine; Pertuzumab; Trastuzumab;
Evolution of anti-HER2 therapies for cancer treatment
Keywords: پروتوزومب; HER2; Monoclonal antibodies; Trastuzumab; Pertuzumab; T-DM1; Imaging;
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study
Keywords: پروتوزومب; Breast cancer; Toxicity; Human epidermal growth factor 2; Neoadjuvant treatment; Trastuzumab; Pertuzumab;
Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures
Keywords: پروتوزومب; Human epidermal receptor 2 (HER2); Left ventricular ejection fraction (LVEF); Trastuzumab; Pertuzumab; Lapatinib; Ado-trastuzumab (T-DM1);
Current challenges in HER2-positive breast cancer
Keywords: پروتوزومب; Breast cancer; Dual targeting; HER2; Lapatinib; Neoadjuvant; Pertuzumab; Trastuzumab; Trastuzumab-emtansine;
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications
Keywords: پروتوزومب; Early breast cancer; Endocrine therapy; HER2-positive; Pertuzumab; T-DM1; Trastuzumab;
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab
Keywords: پروتوزومب; Indium-111; Pertuzumab; Clinical trial application; Radiation dosimetry; Toxicology; Pharmacokinetics;
Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)
Keywords: پروتوزومب; Pertuzumab; Indium-111; Good manufacturing practices (GMP); HER2; Radiopharmaceutical kit;
Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
Keywords: پروتوزومب; breast cancer; epidemiology; life-years; pertuzumab; trastuzumab;
Treatment of HER2-positive breast cancer
Keywords: پروتوزومب; HER2-positive breast cancer; Trastuzumab; Pertuzumab; Lapatinib;
HER2 aberrations in cancer: Implications for therapy
Keywords: پروتوزومب; Human epidermal growth factor 2; Cancer; Target therapy; Trastuzumab; Lapatinib; Ado-trastuzumab emtansine; Pertuzumab; Afatinib;
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
Keywords: پروتوزومب; Neoadjuvant breast cancer; Pathological complete response; Trastuzumab; Lapatinib; Pertuzumab; Novel agents; HER2;
Atomic force microscopy study of the effect of HER 2 antibody on EGF mediated ErbB ligand–receptor interaction
Keywords: پروتوزومب; Atomic force microscopy (AFM); Single-molecule force spectroscopy (SMFS); Trastuzumab; Pertuzumab; EGFR/HER2 heterodimerization
Pertuzumab in Breast Cancer: A Systematic Review
Keywords: پروتوزومب; Breast cancer; Perjeta; Pertuzumab; Systematic review
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Keywords: پروتوزومب; Trastuzumab; Pertuzumab; Complement resistance; siRNA; Complement regulatory proteins; LipoplexCDC, complement-dependent cytotoxicity; CD46, membrane cofactor protein; CD55, decay accelerating factor; CD59, protectin; MAC, membrane attack complex; mCRP, m
Dual Blockade of HER2 - Twice as Good or Twice as Toxic?
Keywords: پروتوزومب; Breast cancer; HER2-neu; lapatinib; neratinib; pertuzumab; trastuzumab;
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition
Keywords: پروتوزومب; RTK inhibitor; Pertuzumab; PI3K/PTEN/AKT signalling network; Anticancer drug resistance; Sensitivity analysis; Drug combination
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition
Keywords: پروتوزومب; HER2 inhibitor; Pertuzumab; ERK/PI3K/PTEN/AKT signaling network; Anticancer drug resistance;
Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP
Keywords: پروتوزومب; HRAP; HER2; Paclitaxel; Pertuzumab; Breast cancer; Apoptosis
In silico designing and optimization of anti-breast cancer antibody mimetic oligopeptide targeting HER-2 in women
Keywords: پروتوزومب; Breast cancer; HER-2; Pertuzumab; Oligopeptide designing; Anticancer drug
Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer
Keywords: پروتوزومب; IGF-1R; Lapatinib; Monoclonal antibody; Neratinib; Pertuzumab; T-DM1; Trastuzumab
EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44
Keywords: پروتوزومب; EGFR; ErbB2; Trastuzumab; Pertuzumab; CD44 shedding
Epidermal growth factor receptor pathway inhibitors
Keywords: پروتوزومب; Epidermal growth factor receptor; Trastuzumab; Cetuximab; Panitumumab; Pertuzumab; Gefitinib; Erlotinib